Baird Maintains Outperform Rating on Charles River Laboratories International, Inc. (CRL)
On February 20, Mizuho Securities analyst Ann Hynes maintained her Neutral rating on Charles River Laboratories International, Inc. (NYSE:CRL).
Charles River Laboratories International Inc. (CRL)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Harris Associates Natixis Global Asset Management | 1,677,606 | $334,648,845 | +14% | 0.42% |
| 2. | Ariel Investments John W. Rogers | 1,427,771 | $284,811,759 | -5% | 3.08% |
| 3. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 836,240 | $166,813,155 | +9% | 0.1% |
| 4. | Alyeska Investment Group Anand Parekh | 644,726 | $128,609,942 | +121% | 0.36% |
| 5. | D E Shaw D. E. Shaw | 431,128 | $86,001,414 | -56% | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $165.01 | 6,075 | $1,002,435.75 | 183,639 | 2025-02-20 | Filing | |
| $164.63 | 1,514 | $249,249.82 | 55,058 | 2025-02-20 | Filing | |
| $187.82 | 1,322 | $248,298.04 | 44,449 | 2023-11-20 | Filing | |
| $178.05 | 5,620 | $1,000,641.00 | 202,643 | 2023-11-14 | Filing | |
| $198.79 | 1,000 | $198,786.00 | 1,000 | 2023-08-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $163.72 | 400 | $65,488.00 | 23,716 | 2025-08-22 | Filing | |
| $157.60 | 800 | $126,080.00 | 24,116 | 2025-08-18 | Filing | |
| $150.04 | 400 | $60,016.00 | 24,916 | 2025-08-07 | Filing | |
| $139.05 | 24 | $3,337.20 | 5,575 | 2025-05-15 | Filing | |
| $137.68 | 81 | $11,152.08 | 5,599 | 2025-05-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,887,175 | $1,174,373,670 | 0.02% | |
| 2. | 3,754,354 | $748,918,482 | 0.01% | |
| 3. | 2,696,150 | $537,828,003 | 0.08% | |
| 4. | 1,995,596 | $403,948,542 | 0.65% | |
| 5. | 1,871,688 | $373,364,322 | 0.01% |
News See All
10 Best Life Sciences Stocks to Buy According to Hedge Funds
Following a difficult start in 2025, the ever-evolving life sciences segment recovered strongly in the latter half of the year.
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2025 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2025 Earnings Call Transcript February 18, 2026Charles River Laboratories International, Inc. misses on earnings expectations.
12 Best Mid Cap AI Stocks to Buy According to Hedge Funds
Mega caps dominated most of 2024 and 2025, but with big tech's high valuations and a general belief that they are unlikely to deliver outsized returns in the coming years, hedge funds and analysts are...
What Makes Charles River Laboratories (CRL) an Investment Bet?
Madison Investments, an investment advisor, released its “Madison Small Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Charles River Laboratories International, Inc. (NYSE:CRL) Q3 2025 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL) Q3 2025 Earnings Call Transcript November 5, 2025Charles River Laboratories International, Inc. beats earnings expectations.
Here’s Why ClearBridge Investments Growth Strategy Closed Out Charles River Laboratories International (CRL)
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Charles River Laboratories International, Inc. (NYSE:CRL) Q2 2025 Earnings Call Transcript
Charles River Laboratories International, Inc. (NYSE:CRL) Q2 2025 Earnings Call Transcript August 6, 2025Charles River Laboratories International, Inc. misses on earnings expectations.
Charles River Laboratories International (CRL) is Expected to Gain as Industry Growth Resumes
Oakmark Funds, advised by Harris Associates, released its “Oakmark Equity and Income Fund” Q2 2025 investor letter. A copy of the letter can be downloaded here.
Polen U.S SMID Company Growth Strategy Sold Charles River Laboratories International (CRL) for More Attractive Opportunities
Polen Capital, an investment management company, released its “Polen US SMID Company Growth Strategy” first-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Hedge Fund Resource Center